Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Not Applicable

Completed

Brief Summary: The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Detailed Description: This study is an open-label pilot study. Participants will be treated with oral tofacitinib for 3 months.

Recruitment & Eligibility

Inclusion Criteria

Age >= 18 years old
Diagnosis of alopecia areata with >50% scalp involvement, alopecia totalis, or alopecia universalis
Hair loss present for at least 6 months
No treatment for alopecia areata in past 2 months
No evidence of hair regrowth
Females of childbearing potential must use birth control while taking the medication and there must be a negative pregnancy test documented prior to starting the medication
Fluent in spoken and written English

Exclusion Criteria

Age <18 years old
Patients have received treatment known to affect alopecia areata within 2 months of enrolling in the study
Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)
Patients known to be HIV or hepatitis B or C positive
Patients with positive tuberculin skin test or positive QuantiFERON TB test
Patients with leukopenia or anemia
Patients with renal or hepatic impairment
Patients with peptic ulcer disease
Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNH-alpha inhibitors
Women of childbearing potential who are unable or unwilling to use birth control while taking the medication
Women who are pregnant or nursing

Arm && Interventions

Group	Intervention	Description
Tofacitinib	Tofacitinib	Participants will receive tofacitinib for 3 months.

Primary Outcome Measures

Name	Time	Method
Percent Change in Severity of Alopecia Tool (SALT) Score	0 and 3 months	SALT score range is from 0 (no hair loss) to 100 (100% hair loss). Positive percent change from baseline corresponds to reduction in SALT score.

Secondary Outcome Measures